Sierra Oncology

June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Does amount matter when it comes to a biotech IPO?

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Where is the IPO class of 2014-15 now?

Select small caps stand out amid wider 2016 stock market declines

Patience rewards Ionis and Ziarco

Returns hint at gradual decline in quality of biotech floats

Lively M&A scene keeps biotech shares buoyant in Q3

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Bristol-Myers buys back Medarex discard

Asco event analyser – 2016’s winners and losers

Biotech IPOs slow, but appetite for size remains unsatisfied

Latest Reports

Evaluate Vantage COVID-19 Report

Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review

Editor's Picks

Covid-19 antibody tests face a very specific problem

Covid-19’s clinical damage starts to emerge

The crucial data readouts coming soon for small biotechs

AACR 2020 preview – no Tigit, but plenty of novel mechanisms

The long path to an effective coronavirus vaccine